Join

Compare · ACON vs ILMN

ACON vs ILMN

Side-by-side comparison of Aclarion Inc. (ACON) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ACON and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
  • ILMN is the larger of the two at $23.91B, about 2890.2x ACON ($8.3M).
  • ILMN has been more active in the news (22 items in the past 4 weeks vs 7 for ACON).
  • ILMN has more recent analyst coverage (25 ratings vs 0 for ACON).
MetricACONILMN
Company
Aclarion Inc.
Illumina Inc.
Price
-
-
Market cap
$8.3M
$23.91B
1M return
-
-
1Y return
-
-
Industry
Medical Specialities
Medical Specialities
Exchange
NASDAQ
NASDAQ
IPO
2022
2000
News (4w)
7
22
Recent ratings
0
25
ACON

Aclarion Inc.

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

ILMN

Illumina Inc.

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.

Latest ACON

Latest ILMN